- IGF1R protein expression is not associated with differential benefit to concurrent trastuzumab in early-stage HER2+ breast cancer from the North Central Cancer Treatment Group (Alliance) adjuvant trastuzumab trial N9831. Clinical Cancer Research. 2017 Academic Article GET IT
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (Alliance) N9831.
Clinical Cancer Research.
Times cited: 13